C4U and Rebirthel Entered Into a Memorandum of Understanding Aiming for the Collaborative Research

C4U Corporation (“C4U”) and Rebirthel Co., Ltd. (“Rebirthel”) are pleased to announce that we have entered into a memorandum of understanding to explore the possibility of collaborative research and development. 
C4U is promoting the development of novel therapies for various diseases, including genetic diseases, utilizing CRISPR-Cas3, a unique genome editing technology, both in-house and in collaboration with other companies. 
Rebirthel aims to develop “universal” killer T cells regenerated from pluripotent stem cells, to be used as “off-the-shelf T cells” for the treatment of cancer and viral infections. 
Through this collaborative research, we intend to develop novel regenerative killer T cell products utilizing both C4U's CRISPR-Cas3 gene editing technology and Rebirthel’s technology for regenerating killer T cells from pluripotent stem cells. We will advance our collaboration toward a definitive agreement.

About C4U 
C4U is a privately held biotech company based in Osaka, Japan, and is focused on the development of safe and efficient gene therapies utilizing its proprietary next generation CRISPR-Cas3 gene editing platform. In comparison to the CRISPR-Cas9 platform, CRISPR-Cas3 presents the distinct benefits of: 1) no off-target by the higher selectivity of deletion site (improved safety); 2) efficient knockouts by the larger deletion of gene sequences; and 3) an entirely independent patent portfolio. C4U has been granted a worldwide exclusive license to CRISPR-Cas3 by Osaka University for use in eukaryotic cells thus simplifying sublicensing transactions which is in sharp contrast to the complex and heavily litigated CRISPR-Cas9 patent landscape.
URL: https://www.crispr4u.jp/en/

About Rebirthel 
Rebirthel Co., Ltd. is a biotechnology venture company originating from Kyoto University. Rebirthel develops “allogeneic immune cell therapy” using killer T cells regenerated from pluripotent stem cells.
While overcoming immune rejection remains a challenge with the allogeneic strategy, Rebirthel has the technology to address this issue and aims to provide novel therapy, which is "universal" and "off-the-shelf" type for patients with advanced cancers that are difficult to cure with conventional therapies, as well as for patients suffering from viral infectious diseases that become prolonged due to immunodeficiency. Multiple fundamental technologies to realize this therapy have been patented in countries all over the world.
Rebirthel has multiple pre-clinical stage pipelines under in-house development, as well as licensing and partnering pipelines with overseas and domestic pharmaceutical or biotech companies, through licensing out of its patented technologies.
URL: https://rebirthel.com/en/